Aptarion Biotech AG is a clinical-stage drug development company leveraging the unique properties of mirror-image (L-) aptamers. L‑Aptamers are single-stranded L-RNA or L-DNA molecules combining high target affinity, specificity and biostability with the ease of a scalable chemical production process.
Our lead program AON-D21 has completed Phase 1 clinical development. The first trial in patients shall commence in 2023.
AON-D21 neutralizes complement factor C5a, a central player of the immune system. C5a is believed to trigger excessive immune responses in severe inflammatory diseases and infections, and to be involved in immune evasion mechanisms of tumors.
Aptarion is headquartered in Berlin, Germany.